MAPT and Alzheimer disease: Armstrong et al. (2014) report that the increase in LAMP2 protein levels in AD patients CSF correlates with the well established early AD biomarker p-tau181 (tau phosphorylation at amino acid residue Thr181). This tau phosphorylation biomarker (p-tau181), together with the p-tau217 possess among other tau phosphorylation biomarkers the highest diagnostic power to discriminate between AD and non-AD dementias at an early stage (Struyfs et al., 2015; Palmqvist et al., 2020); thus LAMP2 elevation in CSF could be as useful as ptau181 and probably ptau217 for early AD diagnosis.